Vanda announces positive pivotal study results for HETLIOZ® (tasimelteon) in patients
Vanda Pharmaceuticals announced that HETLIOZ® (tasimelteon) improved sleep quality and increased sleep duration in patients with Smith-Magenis Syndrome in a pivotal placebo controlled clinical study. Tasimelteon met the primary endpoint of improvement in the 50% worst sleep quality. December 10, 2018